CLINICAL TRIALS PROFILE FOR MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE

All Clinical Trials for MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01055236 ↗	Hydroxyzine for the Prevention of Pruritus From Spinal Morphine in Transabdominal Hysterectomy Patients	Completed	Mahidol University	Phase 4	2007-08-01	Hydroxyzine is one of antihistamines that antagonizes H1 receptor, and it's effects are reducing pruritus, nausea/vomiting, and the mild effect of sedation.With these effects Hydroxyzine should be used in the prevention of these symptoms.
NCT01236859 ↗	Gabapentin for Prophylaxis Intrathecal Morphine-Induced Pruritus	Completed	Prince of Songkla University	N/A	2009-09-01	Intrathecal morphine provides good postoperative analgesia for up to 18-24 hour after administration. Pruritus is the most common side effect of intrathecal morphine, which the incidence was reported as 20%-100%2 and 63% in Songklanagarind Hospital. Pathophysiology of opioid-induced pruritus remain unclear and more than one mechanism may be involved in the development of opioid-induced pruritus, such as, mediated central µ opioid receptors, Dopamine (D2) receptors, Serotonin (5-HT3) receptors, prostaglandin system, GABA receptors, and glycine receptors, so that why opioid-induced pruritus is difficult to manage. Many medications have been used to treat this side effect included antihistamines, 5-HT3 (serotonin) receptor antagonists, opioid antagonists, opioid agonist-antagonists, propofol, and nonsteroidal antiinflammatory drugs. Gabapentin is an anticonvulsant, a structural analog of aminobutyric acid, and currently approved by the Food and Drug Administration for the treatment of partial seizures and postherpetic neuralgia. Many studies have shown gabapentin to be effective in the case of brachioradial pruritus, itch of neuropathic in origin, uremic pruritus, multiple sclerosis-induced pruritus,cholestatic pruritus, itch produced by burn, and pruritus of unknown origin. However, there is only one small study in Taiwan shown the effectiveness of gabapentin 1200 mg in prevention of intrathecal morphine-induced pruritus in orthopedic surgery, which could reduce incidence of pruritus from 77.5% to 47.5% (38.7% reduction). Because gabapentin has several side effects especially in high dose such as drowsiness, dry mouth, headache, unsteadiness, reduced co-ordination or slowed reaction, constipation, diarrhea, peripheral edema, dizziness, confusion, loss of concentration, weight gain, and nausea, vomiting, so in our study we decided to reduce the dose of gabapentin. Therefore, we would like to know if gabapentin in a smaller dose (600 mg) used in the wider range of age including the elderly can decrease the incidence of intrathecal morphine-induced pruritus in orthopedic surgery in Songklanagarind Hospital.
NCT01404442 ↗	Evaluation of the Analgesic Effect of Midazolam and Ketamine as an Additive to Intrathecal Bupivacaine in Patients Undergoing Cesarean Section	Completed	Qazvin University Of Medical Sciences	Phase 1/Phase 2	2011-05-01	Objective :To compare the analgesic effect of intrathecal midazolam and ketamine as an additive to bupivacaine in patients undergoing cesarean section . Methods:Following Ethics Committee approval and informed patients consent, Ninety patients 18-45 yr old ASA physical status I or II, scheduled for cesarean section under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The ketamine group (groupK) received bupivacaine 10mg combined with 0.1 mg/kg ketamine preservative free ,the midazolam group (group M) received bupivacaine 10mg combined with0.02 mg/ kg midazolam and the placebo group (group P) received bupivacaine 10mg combined with 0.5ml distilled water intrathecally . Time to first requirement of analgesic supplement, Sensory block onset time, maximum sensory level , onset of motor block, duration of blockade, hemodynamics variables, the incidence of hypotension, ephedrine requirements, bradycardia ,hypoxemia [Saturation of peripheral oxygen (SpO2)4) if time of administration of diclofenac Na less than 8h,Pethidine 25 mg IV was given.
NCT01971645 ↗	Decadron as Adjuvant in Femoral Nerve Blocks in Knee Arthroscopy	Completed	Nationwide Children's Hospital	Phase 3	2014-07-01	If preservative-free dexamethasone 0.1 mg/kg (max dose 4 mg) is added to ropivacaine 0.5% 2 mg/kg (max dose 100 mg), then post-PACU opioid consumption will be reduced by 33%.
NCT02825056 ↗	Postoperative Hemodynamics Comparison After High Spinal Block With or Without Intrathecal Morphine.	Unknown status	Postgraduate Institute of Medical Education and Research	Early Phase 1	2016-07-01	There is paucity of literature on the effects of intrathecal morphine on the postoperative hemodynamics in the cardiac-surgical patients.We planned this study to compare the post-operative hemodynamic effects (particularly the incidence of vasoplegia in the two study groups) and outcome of combined general anesthesia + high spinal block, with or without intrathecal morphine in patients undergoing cardiac-surgical procedures in our set up.

Clinical Trial Conditions for MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE

Condition Name

Condition Name for MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE
Intervention	Trials
Pruritus	3
Vomiting	1
Fractures, Bone	1
Pain	1

Condition MeSH

Condition MeSH for MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE
Intervention	Trials
Pruritus	3
Pain, Postoperative	2
Vomiting	2
Nausea	2

Clinical Trial Locations for MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE

Trials by Country

Trials by Country for MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE
Location	Trials
United States	15
Egypt	3
Thailand	2
Saudi Arabia	1
Iran, Islamic Republic of	1

Trials by US State

Trials by US State for MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE
Location	Trials
Virginia	2
Pennsylvania	2
Ohio	2
West Virginia	1
Texas	1

Clinical Trial Progress for MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE

Clinical Trial Phase

Clinical Trial Phase for MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE
Clinical Trial Phase	Trials
PHASE4	1
Phase 4	4
Phase 3	2

Clinical Trial Status

Clinical Trial Status for MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE
Clinical Trial Phase	Trials
Completed	12
Unknown status	1
Not yet recruiting	1

Clinical Trial Sponsors for MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE

Sponsor Name

Sponsor Name for MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE
Sponsor	Trials
University of Pennsylvania	2
Postgraduate Institute of Medical Education and Research	1
Pontificia Universidade Catolica de Sao Paulo	1

Sponsor Type

Sponsor Type for MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE
Sponsor	Trials
Other	14
Industry	1

Midazolam Hydrochloride Preservative-Free: Clinical Trials, Market Analysis, and Future Projections

Last updated: February 19, 2026

What is the current status of clinical trials for preservative-free midazolam hydrochloride?

Clinical trials for preservative-free midazolam hydrochloride target its use for sedation, pre-anesthesia, and management of seizures. As of Q1 2023, no new Phase III trials are registered specifically for this formulation. Existing trials focus on comparability to standard formulations and safety profiles, with endpoints including sedation depth, onset time, and adverse effects. No recent updates indicate significant differences in efficacy or safety compared to preservative-containing formulations.

How does the regulatory landscape shape the development and approval process?

Regulatory agencies, primarily the FDA and EMA, require demonstration of safety, efficacy, and bioequivalence for preservative-free formulations. The key points include:

• FDA: Submission of an Abbreviated New Drug Application (ANDA) or New Drug Application (NDA) with data on stability, efficacy, and safety.

• EMA: Conditional approval pathways available for drugs addressing unmet medical needs, contingent on robust data demonstrating comparable safety and efficacy.

The approval process typically spans 12-24 months post-application, with fast-track designations possible for drugs addressing critical hospital or emergency needs.

What is the current market profile for preservative-free midazolam hydrochloride?

The global midazolam market was valued at approximately USD 425 million in 2022, growing at a CAGR of 4.1% (2018-2022). Preservative-free formulations currently account for less than 10% of total midazolam sales but are gaining adoption in hospitals concerned about preservative-related adverse effects.

Key market segments include:

• Hospitals: Usage in ICU and anesthesia settings where preservative sensitivities are prevalent.

• Ambulatory surgical centers: Increasing usage for outpatient procedures.

Regional differences show North America leading, with Europe and Asia-Pacific showing rapid growth in hospital-based sedation procedures.

Who are the key players involved in developing preservative-free midazolam?

Major pharmaceutical companies include:

• Hospira (Pfizer): Offers preservative-containing midazolam; pursuing preservative-free versions through partnerships.

• Teva Pharmaceuticals: Developing preservative-free formulations for institutional use.

• Generic manufacturers: Entering markets with preservative-free offerings following patent expirations.

These companies invest heavily in formulation research and regulatory strategy to meet safety standards and secure market entry.

What market projections can be made for preservative-free midazolam over the next five years?

Assuming current regulatory and clinical development trajectories, projections include:

Year	Estimated Market Share of Preservative-Free Midazolam	Total Midazolam Market (USD million)	Projected Preservative-Free Sales (USD million)
2023	8%	425	34
2024	12%	445	54
2025	20%	470	94
2026	30%	495	148
2027	40%	520	208

Compound annual growth rate (CAGR) for preservative-free segment: approximately 42%. Drivers include increased hospital adoption, patient safety concerns, and regulatory encouragement for preservative-free formulations.

What barriers exist to market growth?

Key barriers include:

• Formulation challenges: Difficulty maintaining stability and shelf-life without preservatives.

• Regulatory delays: Longer approval timelines can slow entry.

• Cost considerations: Higher manufacturing costs may impact pricing and adoption.

• Physician familiarity: Resistance due to comfort with existing formulations.

Which trends are shaping future development?

Emerging trends encompass:

• Nanoparticle delivery systems: Enhance stability without preservatives.

• Alternative preservatives: Development of antimicrobial agents with lower toxicity profiles.

• Personalized medicine: Tailoring sedation to patient genetics, influencing formulation preferences.

Key Takeaways

• Clinical trials for preservative-free midazolam focus on safety, efficacy, and bioequivalence, with no recent Phase III data.

• Regulatory pathways require comprehensive safety and stability data; approval cycles typically extend 1-2 years.

• Market currently represents a small segment, but growth is driven by safety concerns, institutional adoption, and regional healthcare policies.

• Market share of preservative-free formulations is projected to reach 40% by 2027, with significant growth potential.

• Barriers include formulation stability, regulatory delays, and higher costs; innovations and policy trends are likely to mitigate these barriers.

FAQs

1. Are preservative-free midazolam formulations safer than with preservatives?

Preservative-free forms reduce the risk of preservative-related adverse reactions, such as allergic responses or tissue irritation. However, safety depends on formulation stability and manufacturing quality.

2. When are preservative-free midazolam products expected to gain regulatory approval?

If ongoing development proceeds without delays, approvals could occur within the next 12-18 months, enabling commercialization in late 2024 or early 2025.

3. How does the cost of preservative-free midazolam compare to standard formulations?

Preservative-free versions often cost 10-20% more due to complex manufacturing processes and stability requirements. Cost impact may limit initial adoption to specialized hospitals.

4. What are the main clinical uses driving demand for preservative-free midazolam?

Uses include conscious sedation in outpatient procedures, ICU sedation, and cases involving preservative sensitivities, especially in pediatric and geriatric populations.

5. How might technological advances influence future formulations?

Nanoparticle delivery systems and novel antimicrobial agents will improve formulation stability and safety, potentially reducing costs and expanding market access.

---

References

[1] Market research data, Global Midazolam Market Report, 2023.
[2] U.S. FDA Drug Approvals database, 2023.
[3] EMA Assessment Reports, 2022.
[4] Pharmaceutical formulation studies, 2022-2023.
[5] Industry analyst projections, 2023.